Basic research of either bevacizumab or gefitinib in platinum-resistant ovarian cancer.

点击翻译按钮获取中文摘要

Combination therapy with bevacizumab and cisplatin for 3 weeks was associated with complete disappearance of all macroscopic evidence of disease in the nude mouse xenograft model. Twenty-nine EGFR mutations were detected in 24 of 102 patients with ovarian cancer. EGFR gene mutation status was not significantly related to survaival time. Topotecan inhibits Akt kinase activity and VEGF transcriptional activation after Cisplatin treatment in platinum-resistant ovarian cancers. These results provide a rationale for using Topotecan in clinical regimens aimed at molecular targeting agents in platinum-resistant ovarian cancers.